CD38 and Miyoshi myopathy: Combination therapies (i.e., anti-CD38 MoAbs plus IMiDs and/or proteasome inhibitors) are needed to lessen the tumor burden in MM, and the rate of relapses justifies an escalation approach to improve patient survival.